



25 December 2018. Clinical records were linked to the Kilifi Health and Demographic Surveillance System and  
26 population incidence rates of CHIKV infection estimated.

27 *Findings.* There were 18,341 paediatric admissions during the 5-year study period, of which 4,332 (24%)  
28 had CSF collected. The most common clinical reasons for CSF collection were impaired consciousness,  
29 seizures and coma (47%, 22% and 21% of all collections, respectively). After acute investigations done for  
30 immediate clinical care, CSF samples were available for 3,980 admissions, of which 367 (9.2%) were  
31 CHIKV RT-PCR positive. The annual incidence of CHIKV-associated neurological disease varied between  
32 13 to 58 episodes per 100,000 person-years among all children <16 years old. Among children aged <5  
33 years, the incidence of CHIKV-associated neurological disease was 77 per 100,000 person-years, compared  
34 with 20 per 100,000 for cerebral malaria and 7 per 100,000 for bacterial meningitis during the study period.

35 *Interpretation.* Although not previously recognized, CHIKV-associated neurological disease is common in  
36 coastal Kenya and a significant public health burden.

37

## 38 INTRODUCTION

39 Chikungunya virus (CHIKV) is a positive sense RNA virus of the *Alphavirus* genus that was first discovered  
40 in Tanzania in 1953 [1]. CHIKV is transmitted between humans by *Aedes aegypti* and *Ae. albopictus*  
41 mosquitoes [2] which have facilitated its rapid global spread and the numerous chikungunya fever (CHIKF)  
42 epidemics reported to date [3]. In adults, CHIKF is characterized by abrupt onset of fever and debilitating  
43 muscle and joint pain, following an incubation period of about 2 to 10 days [4]. Most infections are self-  
44 limiting, but joint and musculoskeletal pain may persist for months to years in some individuals [4].  
45 However, unlike adults, young children rarely present with musculoskeletal symptoms but are more likely to  
46 be hospitalised with CHIKV-associated neurological disease [5-10]. No specific therapeutics or licensed  
47 vaccines are available for CHIKF and, in the absence of pathognomonic clinical features, confirmatory  
48 diagnosis relies on laboratory detection of CHIKV in clinical samples [4].

49 CHIKV transmission is widely reported in Africa [3], with endemic febrile disease being particularly  
50 common in children [11-14]. In 2004, one of the largest CHIKF epidemics on record began in coastal Kenya  
51 and spread rapidly along the East African coast and to islands in the Indian Ocean [15-17]. During that

52 epidemic, severe neurological manifestations of CHIKF were described in children in La Reunion [6, 18],  
53 including disease in neonates suggesting mother-to-child virus transmission [19, 20]. CHIKV-associated  
54 neurological disease has since been reported in other geographical settings [5, 8], except Africa.  
55 Recent analysis identified a high, previously unrecognized, burden of endemic CHIKF in children presenting  
56 at outpatient primary care facilities in coastal Kenya [14]. Here, we used an established ward surveillance at  
57 Kilifi County Hospital on the north coast of Kenya, to estimate the incidence of CHIKV-associated  
58 neurological disease among children in this setting. Cerebrospinal fluid (CSF) samples taken for clinical  
59 reasons at the hospital are routinely stored and clinical records linked to the Kilifi Health and Demographic  
60 Surveillance System (KHDSS), allowing estimation of population incidence rates [21]. We therefore  
61 systematically tested these stored CSF samples to establish whether evidence of infection by CHIKV is  
62 common among children admitted to hospital with neurological illness in coastal Kenya.

63

## 64 **METHODS**

### 65 **Clinical surveillance**

66 Kilifi County Hospital is a referral public hospital in rural coastal Kenya with approximately 4,000 paediatric  
67 admissions annually. The hospital's catchment area includes the approximately 290,000 KHDSS residents  
68 who account for ~40-50% of all admissions and are enumerated during household census rounds conducted  
69 every four months [21]. Malaria transmission is endemic in the demographic surveillance area with seasonal  
70 rains occurring in April-June and October-December [22]. The paediatric service at Kilifi County Hospital  
71 includes two wards; a 70-bed general ward and a 15-bed high dependency unit (HDU) staffed by research  
72 clinicians and nurses. The HDU admits children with serious illness requiring more intensive monitoring and  
73 management but has no ventilation facilities or renal replacement therapy. Electronic case records are kept  
74 for all admissions including demographics, vital signs, clinical history and examination, as well as routine  
75 laboratory investigations such as malaria blood slides, and blood and CSF culture. Each patient is assigned a  
76 discharge diagnosis by the attending clinician following review of the notes and results. All data are linked to  
77 the KHDSS database in real time by means of unique person identifiers.

78 For this study, all children aged <16 years whose illness required sampling and analysis of CSF were eligible  
79 for inclusion. The decision to collect CSF was made by clinicians. The same senior clinicians oversaw care  
80 throughout the period of surveillance. Where acute coma was present, the medical team considered the risks  
81 of lumbar puncture versus clinical benefits of diagnostic information from a clinical management perspective  
82 without reference to research considerations. Where clinically appropriate, delayed lumbar punctures were  
83 conducted after a period of treatment. Neuroimaging was not available on site during the period of  
84 surveillance. After investigations done for immediate clinical care, an aliquot of CSF was stored at -80°C and  
85 used for CHIKV testing by RT-PCR as described below. Ethical approval was provided by the Kenya  
86 Medical Research Institute Scientific and Ethics Review Unit (SSC No. 3296) and written informed consent  
87 provided by parents or guardians of all study participants.

### 88 **Detection of CHIKV infection**

89 Total RNA was isolated from 100µl of each CSF sample using TRIzol™ Reagent (ThermoFisher). A  
90 published primer-probe set targeting the CHIKV non-structural protein 1 (nsP1) region [23] was then used to  
91 detect CHIKV viral RNA using the Taqman® Fast Virus RT-PCR kit (ThermoFisher) on a 7500 Real-Time  
92 PCR System (Applied Biosystems) in a 10µl reaction volume comprising: 3µl of 4x Taqman® Fast Virus 1-  
93 step master mix, 5µl RNA, and primers (CHIKV 874, CHIKV 961) and probe (CHIKV 899) [23] at final  
94 concentrations of 800nM and 200nM, respectively. RT-PCR conditions were; reverse-transcription at 50°C  
95 for 5 min, RT inactivation/initial activation 95°C for 20 sec and 45 cycles of denaturation at 95°C for 3sec  
96 and annealing/extension at 60°C for 30 sec [14]. A positive result was defined as a cycle threshold (Ct) value  
97 of <40, with viral RNA from a cultured CHIKV isolate and RT-PCR mastermix without template used as  
98 positive and negative controls, respectively [14].

### 99 **Statistical analysis**

100 All children hospitalised during the study period and whose illness required sampling and analysis of CSF  
101 were included in the analysis. Demographic and clinical features were compared between CHIKV positive  
102 and CHIKV negative admissions using Chi2 test for categorical variables and Mann-Whitney U test for  
103 continuous variables. Cerebral malaria was defined as admission with a *Plasmodium falciparum* parasite  
104 density >2,500/µl of blood and a Blantyre Coma Score (BCS) <3, while impaired consciousness was defined  
105 as BCS 3 or 4 [22, 24]. Acute bacterial meningitis was defined as either: i) a positive CSF bacterial culture or

106 latex agglutination test, or ii) bacteraemia accompanied by a CSF-to-blood glucose ratio <0.1, or iii)  
107 bacteraemia accompanied by CSF white blood cell count  $\geq 50 \times 10^6$  cells/L [25, 26]. We required evidence  
108 of bacteria in CSF or in blood in the case definition of meningitis to maximise specificity, since there are no  
109 data on glucose or CSF cell counts for CHIKV infection in our setting. Incidence of CHIKV-associated  
110 neurological disease among KHDSS residents was calculated by dividing the number of CHIKV positive  
111 admissions by the total person-years of observation during the 5-year study period and expressed per  
112 100,000 person-years observed. For comparison, incidence estimates for cerebral malaria and acute bacterial  
113 meningitis were also calculated. Incidence rate ratios were estimated using Poisson regression models and  
114 compared between socio-demographic variables. All analyses were carried out in STATA/IC version 15.1  
115 (StataCorp College Station, Texas, USA). We also examined the geographical distribution of cases of  
116 CHIKV infection, cerebral malaria, meningitis and other admissions across the KHDSS area by mapping  
117 (using QGIS version 3.10) the geolocations of homes where the children lived at the time of admission.  
118 These data on residence are collected and routinely updated by the KHDSS.

#### 119 **Role of the funding source**

120 The funders had no role in the design of the study, data collection, analysis and interpretation, or writing of  
121 the report. The corresponding author had full access to all data in the study and had final responsibility for  
122 the decision to submit for publication.

123

124

## 125 **RESULTS**

126 Between January 2014 and December 2018, 18341 children aged <16 years were admitted at Kilifi County  
127 Hospital, of whom 4332 (24%) had CSF collected for routine investigations (Figure 1). The most common  
128 clinical indications for CSF collection were coma, impaired consciousness and seizures which together  
129 accounted for 90% of all CSF collections (Figure S1). Similar proportions of children with these lumbar  
130 puncture indications had CSF collected across the 5-year study period, suggesting a consistent pattern of  
131 clinical practice throughout (Figure S2). After acute investigations were done for immediate clinical care,

132 stored CSF was available for 3980 (92%) of the 4332 admissions and these were screened for CHIKV  
133 infection (Figure 1).

134 Of the 3980 admissions among children aged <16 years, 367 (9.2%, 95% CI 8.3, 10.2) were CHIKV RT-  
135 PCR positive. Most of these CHIKV infections (308 of the 367; 84%) were in children aged under 5 years  
136 (Table 1). RT-PCR assay cycle threshold values for CHIKV positive samples showed no correlation with age  
137 (Spearman's  $\rho = -0.09$ ,  $p = 0.07$ ). CHIKV RT-PCR positivity was highest in 2016 (18%), when an epidemic  
138 was reported in Kenya [27], and ranged between 4% to 9% in the other years (Table 1). CHIKV infection  
139 showed no association with HIV, bacteraemia or malaria parasitaemia at the time of admission (Table 1).

140 Further, the distribution of clinical history and symptoms recorded at admission and laboratory investigations  
141 undertaken to inform clinical care was similar for CHIKV positive and CHIKV negative children (Table 1).

142 Among children below 3 months of age, the majority (1352/1789; 75%) of CSF samples were taken from  
143 newborns in the first week of life in whom we observed high CHIKV positivity rates (8.7%, 95% CI 7.3,  
144 10.3; Table S2) suggesting mother-to-child CHIKV transmission [28].

145 Overall mortality among all 18341 admissions aged <16 years was 9.0% (95% CI 8.6, 9.4; 1653 deaths).  
146 Mortality among the 4332 admissions that had CSF collected during the study period (Figure 1) was 3.2%  
147 (95% CI 2.7, 3.8; 139 deaths), compared with 10.8% (95% CI 10.3, 11.3; 1514 deaths) in those where CSF  
148 was not collected (Figure S3). A similar pattern was observed among newborns in the first week of life,  
149 where overall mortality was 17.7% (95% CI 16.5, 18.8), whereas mortality in those whose CSF was  
150 collected was 2.5% (39 deaths) compared with 25.3% (773 deaths) in those where CSF was not collected.

151 Overall case fatality among CHIKV positive children was 1.4% (95% CI 0.4, 3.2; 5 deaths of 367 CHIKV  
152 positive children) and 3.2% (95% CI 2.6, 3.8; 115 deaths) among CHIKV negative children (Table 1).

153 To estimate the incidence of CHIKV-associated neurological disease we took the numerator as CHIKV RT-  
154 PCR positive admissions among KHDSS residents (i.e., 207 cases were from KHDSS residents out of the  
155 367 cases presenting to the hospital; Figure 2) and the denominator as the total person-years observed in the  
156 KHDSS during the 5-year study period for children aged <16 years (691,588 person-years; Table 2). The  
157 overall incidence of CHIKV-associated neurological disease within the KHDSS was 30 per 100,000 person-  
158 years (95% CI 26.1, 34.3) and showed no significant variation by sex or season (Table 2). Disease incidence  
159 was highest during the 2016 epidemic but a substantial number of presentations with CHIKV infection were

160 also detected in other years (Table 2). CHIKV-associated neurological disease cases were distributed  
161 throughout the KHDSS area (Figure 2). A strong inverse relationship was observed between the incidence of  
162 CHIKV infection and age, estimated at 77 per 100,000 person-years in all children aged <5 years and 7 per  
163 100,000 person-years among children aged  $\geq 5$  years (Table 2). During the same period, we calculated the  
164 corresponding incidences of cerebral malaria and bacterial meningitis in children aged <5 years to be 20 per  
165 100,000 and 7 per 100,000 person-years, respectively (Table 2). The corresponding incidence of cerebral  
166 malaria and bacterial meningitis in children aged  $\geq 5$  years was 5 per 100,000 and 7 per 100,000 person-  
167 years, respectively (Table 2).

168

## 169 **DISCUSSION**

170 We show that CHIKV is endemic in coastal Kenya, with viral RNA detected in approximately 9% of all CSF  
171 samples in a county referral hospital. We also find that the risk of CHIKV infection is highest in infants with  
172 disease being rare in older children, consistent with acquisition of immunity [14]. We show that CHIKV  
173 infections are common among newborns in our setting, within the first week of life, suggesting mother-to-  
174 child virus transmission as has been observed by others [19, 28]. None of the clinical or laboratory features  
175 available in our dataset could reliably distinguish CHIKV-associated illness from other causes of  
176 neurological disease, including meningism, seizures or coma, though fontanelle bulging was common among  
177 CHIKV positive neonates. Hence in the absence of specific laboratory diagnostics the disease burden of  
178 CHIKV among children with neurological illness is hidden.

179 92% of children had meningism, coma, seizures or mild reductions in Blantyre Coma Score that did not meet  
180 the threshold for coma as the indication for CSF collection. The mortality among CHIKV positive children  
181 was low, despite coma in 22% and depressed levels of consciousness in 47%. The decision to collect CSF  
182 via lumbar puncture was based on clinical priorities rather than research criteria. Even in those without  
183 obvious indications for CSF collection, the illness must have appeared sufficiently significant to clinicians to  
184 justify hospital admission and lumbar puncture. No specific treatment is available for CHIKV infection.  
185 Diagnosis would improve antibiotic stewardship and avoid treatment costs. However, the sickest patients are  
186 likely to die before CSF can be collected as clinicians are less likely to collect CSF in the first 24 hours when  
187 a patient presents in acute coma. During the 5-year period of monitoring 632 children with coma did not

188 have CSF collected, of whom 248 (i.e., 39.2%) died, compared to 530 children with coma who did have CSF  
189 collected, 20 of whom died (i.e., 3.7%) (see Figure S3). Children with coma may not have CSF collected  
190 acutely if clinicians are concerned about raised intracranial pressure, and on clinical recovery clinicians or  
191 families may decide to forego lumbar puncture. Our data suggest that children in whom CSF is not collected  
192 are at high risk of death, and it is therefore possible that CHIKV is a cause of mortality among these  
193 children. Future studies using IgM serology against CHIKV will help address this.

194 When comparing CHIKV-positive and CHIKV-negative children, none of the clinical symptoms or  
195 laboratory tests showed differences that were substantial enough for diagnostic use in clinical practice.  
196 Diagnostic uncertainty in the absence of CHIKV RT-PCR testing (or other laboratory tests such as CHIKV  
197 IgM serology) may be clinically challenging. For instance, treating children for possible culture-negative  
198 bacterial meningitis is costly and contributes to antimicrobial resistance in a hospital setting. Neuroimaging  
199 is difficult to access in our setting and usually requires costs to be borne by parents. Capacity for definitive  
200 molecular or serological testing is therefore required for confirmatory diagnosis of a disease that appears to  
201 be a common cause of admission in young children in coastal Kenya.

202 We observed CHIKV infections during and outside an epidemic year suggesting endemic CHIKV  
203 transmission in coastal Kenya. With the linkage to demographic surveillance, we estimate an incidence of 77  
204 CHIKV-positive admissions per 100,000 person-years among children aged <5 years. This incidence is  
205 higher than recent incidences for bacterial meningitis which we estimate at 7 per 100,000 person-years, or  
206 for invasive bacterial diseases such as 37 per 100,000 for invasive salmonellosis or 3 per 100,000 for  
207 invasive pneumococcal disease [25, 29], and almost four times the incidence of cerebral malaria (20 per  
208 100,000) in the same age group [22]. Following the reductions in severe malaria due to falling malaria  
209 transmission [22], and reductions in bacterial meningitis after vaccination [25], CHIKV may now be one of  
210 the most common causes of hospitalization with neurological disease among children aged <5 years in  
211 coastal Kenya.

212 The study has some limitations. We defined cases based on PCR detection of viral RNA which likely  
213 underestimated the true burden of CHIKV due to the short duration of viral RNA detection in tissues during  
214 CHIKV infections [30]. Furthermore, we are likely to have underestimated more severe CHIKV infections  
215 since CSF is unlikely to be collected from the most severely unwell children. We did not screen for other



216 viruses that have been associated with neurological disease in Africa (e.g., adenovirus, herpesvirus and  
217 others [31]), and this warrants future study. Further studies are also needed to determine the nature and  
218 timing of mother-to-child CHIKV transmission, including maternal CHIKV screening as done by others  
219 [20]. The study was limited to a single geographical location on the Kenyan coast and our estimate of disease  
220 incidence was based on the KHDSS population as denominator, which generally accounts for 40-50% of all  
221 admissions at Kilifi County Hospital. However, CHIKV infections showed little geographical heterogeneity  
222 within the County, supporting generalizability of these results.

223 CHIKV mosquito vectors are widely distributed on the East African coast and reporting of cases of CHIKV  
224 infections in Africa is widespread. Despite this, surveillance for CHIKV in CSF samples has not been  
225 undertaken systematically in Africa and should now be an urgent priority to describe this previously  
226 unidentified public health burden. Such work will provide the foundation for future research on preventive  
227 and therapeutic interventions.

228

## 229 **ACKNOWLEDGEMENTS**

230 This work was commissioned by the National Institute for Health Research (NIHR) Global Health Research  
231 programme (16/136/33) using UK aid from the UK Government. The views expressed in this publication are  
232 those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.  
233 GMW is supported by an Oak foundation fellowship and a Wellcome Trust grant (grant number  
234 203077\_Z\_16\_Z). This manuscript was submitted for publication with permission from the Director of the  
235 Kenya Medical Research Institute. This research was funded in part by the Wellcome Trust grant number  
236 203077\_Z\_16\_Z. For the purpose of Open Access, the author has applied a CC-BY public copyright licence  
237 to any author accepted manuscript version arising from this submission.

238

## 239 **AUTHORS' CONTRIBUTIONS**

240 DKN: Investigation, Formal Analysis, Methodology, Writing - review & editing

241 MO: Formal Analysis, Visualisation, Methodology, Writing - review & editing

- 242 LM: Data Curation, Writing - review & editing
- 243 SMK: Formal Analysis, Writing - review & editing
- 244 BO: Formal Analysis, Writing - review & editing
- 245 DOO: Investigation, Methodology, Writing - review & editing
- 246 GG: Investigation, Validation, Writing - review & editing
- 247 BK: Data Curation
- 248 HKK: Investigation, Writing - review & editing
- 249 JNG: Investigation, Writing - review & editing
- 250 ZRL: Investigation, Writing - review & editing
- 251 AD: Visualisation, Writing - review & editing
- 252 SM: Investigation, Writing - review & editing
- 253 CNA: Investigation, Validation, Writing - review & editing
- 254 SMT: Supervision, Writing - review & editing
- 255 MMH: Project Administration, Writing - review & editing
- 256 CRN: Supervision, Writing - review & editing
- 257 PB: Conceptualisation, Formal Analysis, Writing - review & editing
- 258 GMW: Conceptualisation, Funding acquisition, Supervision, Investigation, Project Administration, Formal
- 259 Analysis, Writing - original draft, Writing - review & editing
- 260
- 261 **CONFLICT OF INTEREST**

262 All authors declare no conflicts of interest.

263

## 264 REFERENCES

- 265 1. Ross RW. The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to  
266 the epidemic. *J Hyg (Lond)*. 1956;54(2):177-91. Epub 1956/06/01. doi: 10.1017/s0022172400044442.  
267 PubMed PMID: 13346078; PubMed Central PMCID: PMCPMC2218030.
- 268 2. Weaver SC, Chen R, Diallo M. Chikungunya Virus: Role of Vectors in Emergence from Enzootic  
269 Cycles. *Annu Rev Entomol*. 2020;65:313-32. Epub 2019/10/09. doi: 10.1146/annurev-ento-011019-025207.  
270 PubMed PMID: 31594410.
- 271 3. Wahid B, Ali A, Rafique S, Idrees M. Global expansion of chikungunya virus: mapping the 64-year  
272 history. *Int J Infect Dis*. 2017;58:69-76. Epub 2017/03/16. doi: 10.1016/j.ijid.2017.03.006. PubMed PMID:  
273 28288924.
- 274 4. Weaver SC, Lecuit M. Chikungunya virus and the global spread of a mosquito-borne disease. *N*  
275 *Engl J Med*. 2015;372(13):1231-9. Epub 2015/03/26. doi: 10.1056/NEJMra1406035. PubMed PMID:  
276 25806915.
- 277 5. Kumar S, Agrawal G, Wazir S, Kumar A, Dubey S, Balde M, et al. Experience of Perinatal and  
278 Neonatal Chikungunya Virus (CHIKV) Infection in a Tertiary Care Neonatal Centre during Outbreak in  
279 North India in 2016: A Case Series. *J Trop Pediatr*. 2019;65(2):169-75. Epub 2018/06/13. doi:  
280 10.1093/tropej/fmy032. PubMed PMID: 29893939.
- 281 6. Gerardin P, Couderc T, Bintner M, Tournebize P, Renouil M, Lemant J, et al. Chikungunya virus-  
282 associated encephalitis: A cohort study on La Reunion Island, 2005-2009. *Neurology*. 2016;86(1):94-102.  
283 Epub 2015/11/27. doi: 10.1212/WNL.0000000000002234. PubMed PMID: 26609145.
- 284 7. Cerny T, Schwarz M, Schwarz U, Lemant J, Gerardin P, Keller E. The Range of Neurological  
285 Complications in Chikungunya Fever. *Neurocrit Care*. 2017;27(3):447-57. Epub 2017/07/26. doi:  
286 10.1007/s12028-017-0413-8. PubMed PMID: 28741102.
- 287 8. Dorleans F, Hoen B, Najioullah F, Herrmann-Storck C, Schepers KM, Abel S, et al. Outbreak of  
288 Chikungunya in the French Caribbean Islands of Martinique and Guadeloupe: Findings from a Hospital-

- 289 Based Surveillance System (2013-2015). *Am J Trop Med Hyg.* 2018;98(6):1819-25. Epub 2018/04/26. doi:  
290 10.4269/ajtmh.16-0719. PubMed PMID: 29692295; PubMed Central PMCID: PMC6086161.
- 291 9. Mehta R, Gerardin P, de Brito CAA, Soares CN, Ferreira MLB, Solomon T. The neurological  
292 complications of chikungunya virus: A systematic review. *Rev Med Virol.* 2018;28(3):e1978. Epub  
293 2018/04/20. doi: 10.1002/rmv.1978. PubMed PMID: 29671914; PubMed Central PMCID:  
294 PMC6086161.
- 295 10. Samra JA, Hagood NL, Summer A, Medina MT, Holden KR. Clinical Features and Neurologic  
296 Complications of Children Hospitalized With Chikungunya Virus in Honduras. *J Child Neurol.*  
297 2017;32(8):712-6. Epub 2017/05/02. doi: 10.1177/0883073817701879. PubMed PMID: 28459170.
- 298 11. Chipwaza B, Mugasa JP, Selemani M, Amuri M, Mosha F, Ngatunga SD, et al. Dengue and  
299 Chikungunya fever among viral diseases in outpatient febrile children in Kilosa district hospital, Tanzania.  
300 *PLoS Negl Trop Dis.* 2014;8(11):e3335. Epub 2014/11/21. doi: 10.1371/journal.pntd.0003335. PubMed  
301 PMID: 25412076; PubMed Central PMCID: PMC4239002.
- 302 12. Hertz JT, Munishi OM, Ooi EE, Howe S, Lim WY, Chow A, et al. Chikungunya and dengue fever  
303 among hospitalized febrile patients in northern Tanzania. *Am J Trop Med Hyg.* 2012;86(1):171-7. Epub  
304 2012/01/11. doi: 10.4269/ajtmh.2012.11-0393. PubMed PMID: 22232469; PubMed Central PMCID:  
305 PMC3247127.
- 306 13. Waggoner J, Brichard J, Mutuku F, Ndenga B, Heath CJ, Mohamed-Hadley A, et al. Malaria and  
307 Chikungunya Detected Using Molecular Diagnostics Among Febrile Kenyan Children. *Open Forum Infect*  
308 *Dis.* 2017;4(3):ofx110. Epub 2017/07/14. doi: 10.1093/ofid/ofx110. PubMed PMID: 28702473; PubMed  
309 Central PMCID: PMC5505337.
- 310 14. Nyamwaya DK, Otiende M, Omuoyo DO, Githinji G, Karanja HK, Gitonga JN, et al. Endemic  
311 chikungunya fever in Kenyan children: a prospective cohort study. *BMC Infect Dis.* 2021;21(1):186. Epub  
312 2021/02/20. doi: 10.1186/s12879-021-05875-5. PubMed PMID: 33602147; PubMed Central PMCID:  
313 PMC7889702.
- 314 15. Kariuki Njenga M, Nderitu L, Ledermann JP, Ndirangu A, Logue CH, Kelly CH, et al. Tracking  
315 epidemic Chikungunya virus into the Indian Ocean from East Africa. *J Gen Virol.* 2008;89(Pt 11):2754-60.  
316 Epub 2008/10/22. doi: 10.1099/vir.0.2008/005413-0. PubMed PMID: 18931072; PubMed Central PMCID:  
317 PMC3347796.

- 318 16. Sang RC, Ahmed O, Faye O, Kelly CL, Yahaya AA, Mmadi I, et al. Entomologic investigations of a  
319 chikungunya virus epidemic in the Union of the Comoros, 2005. *Am J Trop Med Hyg.* 2008;78(1):77-82.  
320 Epub 2008/01/12. PubMed PMID: 18187788.
- 321 17. Sergon K, Yahaya AA, Brown J, Bedja SA, Mlindasse M, Agata N, et al. Seroprevalence of  
322 Chikungunya virus infection on Grande Comore Island, union of the Comoros, 2005. *Am J Trop Med Hyg.*  
323 2007;76(6):1189-93. Epub 2007/06/09. PubMed PMID: 17556634.
- 324 18. Robin S, Ramful D, Le Seach F, Jaffar-Bandjee MC, Rigou G, Alessandri JL. Neurologic  
325 manifestations of pediatric chikungunya infection. *J Child Neurol.* 2008;23(9):1028-35. Epub 2008/02/22.  
326 doi: 10.1177/0883073808314151. PubMed PMID: 18287573.
- 327 19. Ramful D, Carbonnier M, Pasquet M, Bouhmani B, Ghazouani J, Noormahomed T, et al. Mother-to-  
328 child transmission of Chikungunya virus infection. *Pediatr Infect Dis J.* 2007;26(9):811-5. Epub 2007/08/28.  
329 doi: 10.1097/INF.0b013e3180616d4f. PubMed PMID: 17721376.
- 330 20. Gerardin P, Barau G, Michault A, Bintner M, Randrianaivo H, Choker G, et al. Multidisciplinary  
331 prospective study of mother-to-child chikungunya virus infections on the island of La Reunion. *PLoS Med.*  
332 2008;5(3):e60. Epub 2008/03/21. doi: 10.1371/journal.pmed.0050060. PubMed PMID: 18351797; PubMed  
333 Central PMCID: PMCPMC2267812.
- 334 21. Scott JA, Bauni E, Moisi JC, Ojal J, Gatakaa H, Nyundo C, et al. Profile: The Kilifi Health and  
335 Demographic Surveillance System (KHDSS). *Int J Epidemiol.* 2012;41(3):650-7. Epub 2012/05/01. doi:  
336 10.1093/ije/dys062. PubMed PMID: 22544844; PubMed Central PMCID: PMCPMC3396317.
- 337 22. Njuguna P, Maitland K, Nyaguara A, Mwangi D, Mogeni P, Mturi N, et al. Observational study: 27  
338 years of severe malaria surveillance in Kilifi, Kenya. *BMC Med.* 2019;17(1):124. Epub 2019/07/10. doi:  
339 10.1186/s12916-019-1359-9. PubMed PMID: 31280724; PubMed Central PMCID: PMCPMC6613255.
- 340 23. Lanciotti RS, Kosoy OL, Laven JJ, Panella AJ, Velez JO, Lambert AJ, et al. Chikungunya virus in  
341 US travelers returning from India, 2006. *Emerg Infect Dis.* 2007;13(5):764-7. Epub 2007/06/08. doi:  
342 10.3201/eid1305.070015. PubMed PMID: 17553261; PubMed Central PMCID: PMCPMC2738459.
- 343 24. Bejon P, Berkley JA, Mwangi T, Ogada E, Mwangi I, Maitland K, et al. Defining childhood severe  
344 falciparum malaria for intervention studies. *PLoS Med.* 2007;4(8):e251. Epub 2007/08/24. doi:  
345 10.1371/journal.pmed.0040251. PubMed PMID: 17713980; PubMed Central PMCID: PMCPMC1949845.

- 346 25. Hammitt LL, Etyang AO, Morpeth SC, Ojal J, Mutuku A, Mturi N, et al. Effect of ten-valent  
347 pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a  
348 longitudinal surveillance study. *Lancet*. 2019;393(10186):2146-54. Epub 2019/04/20. doi: 10.1016/S0140-  
349 6736(18)33005-8. PubMed PMID: 31000194; PubMed Central PMCID: PMC6548991.
- 350 26. Berkley JA, Mwangi I, Ngetsa CJ, Mwarumba S, Lowe BS, Marsh K, et al. Diagnosis of acute  
351 bacterial meningitis in children at a district hospital in sub-Saharan Africa. *Lancet*. 2001;357(9270):1753-7.  
352 Epub 2001/06/14. doi: 10.1016/S0140-6736(00)04897-2. PubMed PMID: 11403812.
- 353 27. Maljkovic Berry I, Eyase F, Pollett S, Konongoi SL, Joyce MG, Figueroa K, et al. Global Outbreaks  
354 and Origins of a Chikungunya Virus Variant Carrying Mutations Which May Increase Fitness for *Aedes*  
355 *aegypti*: Revelations from the 2016 Mandera, Kenya Outbreak. *Am J Trop Med Hyg*. 2019;100(5):1249-57.  
356 Epub 2019/03/13. doi: 10.4269/ajtmh.18-0980. PubMed PMID: 30860010; PubMed Central PMCID:  
357 PMC6493958.
- 358 28. Contopoulos-Ioannidis D, Newman-Lindsay S, Chow C, LaBeaud AD. Mother-to-child transmission  
359 of Chikungunya virus: A systematic review and meta-analysis. *PLoS Negl Trop Dis*. 2018;12(6):e0006510.  
360 Epub 2018/06/14. doi: 10.1371/journal.pntd.0006510. PubMed PMID: 29897898; PubMed Central PMCID:  
361 PMC6075784.
- 362 29. Muthumbi E, Morpeth SC, Ooko M, Mwanzi A, Mwarumba S, Mturi N, et al. Invasive  
363 Salmonellosis in Kilifi, Kenya. *Clin Infect Dis*. 2015;61 Suppl 4:S290-301. Epub 2015/10/10. doi:  
364 10.1093/cid/civ737. PubMed PMID: 26449944; PubMed Central PMCID: PMC64596936.
- 365 30. Pezzi L, Reusken CB, Weaver SC, Drexler JF, Busch M, LaBeaud AD, et al. GloPID-R report on  
366 Chikungunya, O'nyong-nyong and Mayaro virus, part I: Biological diagnostics. *Antiviral Res*. 2019;166:66-  
367 81. Epub 2019/03/25. doi: 10.1016/j.antiviral.2019.03.009. PubMed PMID: 30905821.
- 368 31. Mallewa M, Vallely P, Faragher B, Banda D, Klapper P, Mukaka M, et al. Viral CNS infections in  
369 children from a malaria-endemic area of Malawi: a prospective cohort study. *Lancet Glob Health*.  
370 2013;1(3):e153-60. Epub 2014/04/22. doi: 10.1016/S2214-109X(13)70060-3. PubMed PMID: 24748325;  
371 PubMed Central PMCID: PMC3986031.

372

373 **TABLES**

374 **Table 1: Demographic and clinical features of patients screened for CHIKV infection**

	<b>CHIKV positive (N=367)</b>	<b>CHIKV negative (N=3613)</b>	<b>P value</b>
<b>Sex – no. (%)</b>			0.39
Female	161 (43.9)	1501 (41.5)	
<b>Age group – no. (%)</b>			0.39
<3 months	148 (40.3)	1641 (45.4)	
3 to <12 months	36 (9.8)	306 (8.5)	
1 to <5 years	124 (33.8)	1164 (32.2)	
5 to <10 years	48 (13.1)	399 (11.0)	
10 to 15 years	11 (3.0)	103 (2.8)	
<b>Year of admission – no. (%)</b>			<0.001
2014	68 (18.5)	918 (25.4)	
2015	91 (24.8)	895 (24.8)	
2016	144 (39.2)	639 (17.7)	
2017	33 (9.0)	457 (12.6)	
2018	31 (8.4)	704 (19.5)	
<b>Season – no. (%)</b>			0.32
Jan - Mar	92 (25.1)	986 (27.3)	
Apr - Jun	110 (30.0)	995 (27.5)	
Jul - Sep	90 (24.5)	792 (21.9)	
Oct - Dec	75 (20.4)	840 (23.2)	
<b>Admission characteristics</b>			
Duration (days) of hospitalization (median, IQR)	3 (2, 6)	4 (2, 7)	0.26
Needed blood transfusion (no., %)	22 (6.0)	185 (5.1)	0.46
<b>General symptoms – no. (%)</b>			
Fever	279 (76.0)	2683 (74.3)	0.46
Vomiting	57 (15.5)	548 (15.2)	0.85
Cough	60 (16.3)	629 (17.4)	0.61
Diarrhea	20 (5.4)	251 (6.9)	0.28
Jaundice	25 (6.8)	312 (8.6)	0.23
Wasting	15 (4.1)	150 (4.1)	0.95
Joint pain	2 (0.5)	10 (0.3)	0.37
Irritability	16 (4.4)	236 (6.5)	0.10
Rash	1 (0.3)	34 (0.9)	0.19
Deep breathing	29 (7.9)	356 (9.8)	0.23

Shock	2 (0.5)	33 (0.9)	0.47
Lymphadenopathy	3 (0.8)	27 (0.7)	0.88
<b>Neurological symptoms – no. (%)<sup>#</sup></b>			
History of seizures	56 (15.3)	469 (13.0)	0.22
Seizures during current illness*	179 (48.8)	1632 (45.2)	0.19
Headache	19 (5.2)	144 (4.0)	0.27
Bulging fontanelle	10 (2.7)	70 (1.9)	0.31
Neck stiffness	3 (0.8)	81 (2.2)	0.07
Agitation	27 (7.4)	239 (6.6)	0.59
Prostration	56 (15.3)	574 (15.9)	0.75
Impaired consciousness	165 (45.0)	1718 (47.5)	0.34
Coma	82 (22.3)	791 (21.9)	0.84
<b>Laboratory investigations – no. (%)<sup>†</sup></b>			
CSF-to-blood glucose ratio <0.67	63 (29.6)	681 (28.7)	0.80
CSF protein > 0.45g/L	154 (43.7)	1607 (46.5)	0.31
CSF Leukocyte count >5/μL	52 (14.7)	567 (16.2)	0.47
CSF turbidity	9 (2.7)	158 (4.8)	0.09
HIV positive	8 (2.8)	73 (2.6)	0.80
Bacteraemia	16 (4.4)	179 (5.0)	0.62
Malaria slide positive	90 (24.7)	815 (22.7)	0.39
Malaria parasite density (>2500/μL)	57 (15.6)	531 (14.8)	0.67
Impaired renal function (creatinine >80μmol/L)	89 (26.5)	894 (28.4)	0.45
Severe anemia (Hb <5g/dL)	13 (3.6)	108 (3.0)	0.56
Hypoglycemia (blood glucose <2.2mmol/l)	15 (6.8)	243 (9.9)	0.12
Thrombocytopenia (platelets <159 x10 <sup>3</sup> /μL)	81 (22.4)	767 (21.5)	0.71
Leukopenia (WBC count<3.9 x10 <sup>3</sup> /μL)	5 (1.4)	53 (1.5)	0.87
Lymphopenia (Lymphocyte count<1.7 x10 <sup>3</sup> /μL)	37 (10.2)	293 (8.2)	0.19

375

376 #Symptoms are not mutually exclusive; some patients had seizures and prostration, neck stiffness and  
377 agitation, and other overlaps in symptoms. \*Refers to at least one seizure in the last 24 hours. The frequency  
378 of multiple seizures (>2 in the last 24 hours) was comparable between CHIKV-positive and CHIKV-negative  
379 patients (35.2% vs 30.2%, p=0.18); the bulk of seizures were generalized (84.2% and 79.3% for CHIKV  
380 negative and positive children, respectively). †Sample sizes for each variable do not always add up to the  
381 total N for each group due to missing data. Analysis was only performed in those with data available.  
382 Missing data are summarised in Table S1 in the Supplementary Appendix. Abbreviations: IQR –



383 interquartile range; HIV – human immunodeficiency virus; Hb – haemoglobin; WBC – white blood cell

384 count.

385

386


**Table 2: Incidence of CHIKV-associated neurological disease among children aged <16 years within the KHDSS during the study period (2014-2018)**



Variable	Categories	Chikungunya (N=207)			Cerebral Malaria (N=68)			Acute Bacterial Meningitis (N=22)		
		n / PYO	Incidence/100,000 (95% CI)	IRR (95% CI)	n / PYO	Incidence/100,000 (95% CI)	IRR (95% CI)	n / PYO	Incidence/100,000 (95% CI)	IRR (95% CI)
Sex	Female	95/341753	27.8 (22.7-34)	1	33/341899	9.7 (6.9-13.6)	1	7/341753	2 (1-4.3)	1
	Male	112/349835	32 (26.6-38.5)	1.2 (0.6-2.4)	35/350019	10 (7.2-13.9)	1 (0.6-1.7)	15/349835	4.3 (2.6-7.1)	2.1 (0.9-5.4)
Age	<3 months	77/10837	710.5 (568.3-888.4)	1	0/10853	-	-	12/10851	110.6 (62.8-194.7)	1
	3 to <12 months	19/33700	56.4 (36-88.4)	0.1 (0-0.1)	2/33755	5.9 (1.5-23.7)	1	2/33750	5.9 (1.5-23.7)	0.1 (0-0.1)
	1 to <5 years	77/179432	42.9 (34.3-53.7)	0.1 (0-0.1)	42/179650	23.4 (17.3-31.6)	3.9 (1-16.3)	1/179697	0.6 (0.1-4)	0 (0-0)
	5 to <10 years	28/227125	12.3 (8.5-17.9)	0 (0-0)	20/227148	8.8 (5.7-13.6)	1.5 (0.3-6.4)	3/227227	1.3 (0.4-4.1)	0 (0-0)
	10 to 15 years	6/240495	2.5 (1.1-5.6)	0 (0-0)	4/240512	1.7 (0.6-4.4)	0.3 (0.1-1.5)	4/240519	1.7 (0.6-4.4)	0 (0-0)
Year	2014	41/138881	29.52 (21.7-40.1)	1	15/138891	10.8 (6.5-17.9)	1	4/138897	2.9 (1.1-7.7)	1
	2015	50/138008	36.2 (27.5-47.8)	1.2 (0.8-1.9)	24/138042	17.4 (11.7-25.9)	1.6 (0.8-3.1)	6/138062	4.3 (2-9.7)	1.5 (0.4-5.4)
	2016	79/136770	57.8 (46.3-72)	2 (1.3-2.9)	12/136847	8.8 (5-15.4)	0.8 (0.4-1.7)	5/136877	3.7 (1.5-8.8)	1.3 (0.3-4.4)
	2017	18/138861	13 (8.2-20.6)	0.4 (0.3-0.8)	7/138965	5 (2.4-10.6)	0.5 (0.2-1.1)	0/138998	-	-
	2018	19/139067	13.7 (8.7-21.4)	0.5 (0.3-0.8)	10/139172	7.2 (3.9-13.4)	0.7 (0.3-1.5)	7/139209	5 (2.4-10.5)	1.7 (0.5-5.4)
Season	Jan - Mar	56/172895	32.4 (24.9-42.1)	1	18/172967	10.4 (6.6-16.5)	1	5/172996	2.9 (1.2-6.9)	1
	Apr - Jun	54/173137	31.2 (23.9-40.7)	1 (0.7-1.4)	15/173216	8.7 (5.2-14.4)	0.8 (0.4-1.7)	9/173245	5.2 (2.7-10)	1.8 (0.6-5.4)
	Jul - Sep	53/172957	30.6 (23.4-40.1)	0.9 (0.6-1.4)	18/173043	10.4 (6.6-16.5)	1 (0.5-1.9)	3/173076	1.7 (0.6-5.4)	0.6 (0.1-2.5)
	Oct - Dec	44/172599	25.5 (19-34.3)	0.8 (0.5-1.2)	17/172692	9.8 (6.1-15.8)	0.9 (0.5-1.8)	5/172726	2.9 (1.2-7)	1 (0.3-3.5)

PYO: person-years observed; IRR: incidence rate ratio

389


390





medRxiv preprint doi: <https://doi.org/10.1101/2021.05.27.20138404>; this version posted June 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Chikungunya



Cerebral Malaria



Meningitis



All admissions whose CSF was taken

 Indian Ocean Coastline

 Kilifi County Hospital

 Kilometres